CALGARY, Alberta, May 03, 2018 (GLOBE NEWSWIRE) -- 10330698 Canada Ltd. (dba Compass Cannabis Clinic, or "the Company") has announced today that, pursuant to the terms of the binding letter agreement dated April 18, 2018 and between the Company and Isodiol International Inc. ("Isodiol"), it has terminated the proposed transaction whereby Isodiol would, after the completion of the transaction, have acquired 19.9% of the issued and outstanding shares of Compass. Accordingly, the transaction between the parties will not be proceeding.
Cautionary Statement Regarding Forward-Looking Information
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Compass Cannabis' actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur. Compass Cannabis assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.
Contact Information
10330698 Canada Ltd.
1650 Pandosy Street
Kelowna, British Columbia V1Y 1P7
Dave Martyn, President
dave.martyn@compasscannabis.ca